Subtopic Deep Dive
Stereotactic Body Radiation Therapy
Research Guide
What is Stereotactic Body Radiation Therapy?
Stereotactic Body Radiation Therapy (SBRT) delivers hypofractionated high-dose radiation in few fractions to extracranial targets like early-stage lung cancers and oligometastases with submillimeter precision.
SBRT achieves high local control rates of 90-95% for inoperable stage I NSCLC (Timmerman, 2010; 2468 citations). Multi-institutional trials confirm efficacy for lung metastases with 1-3 lesions (Rusthoven et al., 2009; 1089 citations). Over 20,000 citations across 10 key papers document its evolution since 2004 (Onishi et al., 2004; 901 citations).
Why It Matters
SBRT provides non-surgical ablation for inoperable lung tumors, yielding 55.8% 3-year survival (Timmerman, 2010). It treats oligometastases in prostate cancer, delaying systemic therapy (Phillips et al., 2020). Respiratory motion management enables thoracic applications (Keall et al., 2006). NTCP models guide safe dose escalation (Marks et al., 2010). Central lung tumor toxicity risks demand refined regimens (Timmerman et al., 2006).
Key Research Challenges
Respiratory Motion Management
Intrafraction motion degrades targeting accuracy in lung SBRT. AAPM Task Group 76a recommends 4D imaging and gating (Keall et al., 2006; 2211 citations). Real-time tracking reduces margins from 1 cm to 5 mm.
Central Tumor Toxicity
Phase II trials report 45% grade 3+ toxicity for central NSCLC lesions with 60 Gy in 3 fractions (Timmerman et al., 2006; 1524 citations). Risk factors include bronchial proximity. Modified fractionation like 50-60 Gy in 5-8 fractions mitigates damage.
NTCP Modeling Accuracy
Normal tissue complication probability models vary 20-50% across datasets for lung SBRT (Marks et al., 2010; 1750 citations). Validation against phase II outcomes reveals overestimation of pneumonitis risk. Patient-specific factors like V20 confound predictions.
Essential Papers
Cancer and Radiation Therapy: Current Advances and Future Directions
Rajamanickam Baskar, Kuo Ann Lee, R. Yeo et al. · 2012 · International Journal of Medical Sciences · 2.7K citations
In recent years remarkable progress has been made towards the understanding of proposed hallmarks of cancer development and treatment. However with its increasing incidence, the clinical management...
Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer
Robert Timmerman · 2010 · JAMA · 2.5K citations
Patients with inoperable non-small cell lung cancer who received stereotactic body radiation therapy had a survival rate of 55.8% at 3 years, high rates of local tumor control, and moderate treatme...
The management of respiratory motion in radiation oncology report of AAPM Task Group 76a)
Paul Keall, G Mageras, James M. Balter et al. · 2006 · Medical Physics · 2.2K citations
This document is the report of a task group of the AAPM and has been prepared primarily to advise medical physicists involved in the external‐beam radiation therapy of patients with thoracic, abdom...
Use of Normal Tissue Complication Probability Models in the Clinic
Lawrence B. Marks, Ellen Yorke, Andrew Jackson et al. · 2010 · International Journal of Radiation Oncology*Biology*Physics · 1.8K citations
Excessive Toxicity When Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung Cancer
Robert Timmerman, Ronald C. McGarry, Constantin T. Yiannoutsos et al. · 2006 · Journal of Clinical Oncology · 1.5K citations
Purpose Surgical resection is standard therapy in stage I non–small-cell lung cancer (NSCLC); however, many patients are inoperable due to comorbid diseases. Building on a previously reported phase...
Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Lung Metastases
Kyle E. Rusthoven, Brian D. Kavanagh, Stuart H. Burri et al. · 2009 · Journal of Clinical Oncology · 1.1K citations
Purpose To evaluate the efficacy and tolerability of high-dose stereotactic body radiation therapy (SBRT) for the treatment of patients with one to three lung metastases. Patients and Methods Patie...
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer
Ryan Phillips, William Y. Shi, Matthew P. Deek et al. · 2020 · JAMA Oncology · 1.1K citations
ClinicalTrials.gov Identifier: NCT02680587.
Reading Guide
Foundational Papers
Read Timmerman (2010; 2468 citations) first for survival benchmarks, Keall (2006; 2211 citations) second for motion essentials, Timmerman (2006; 1524 citations) third for toxicity lessons—these total 6203 citations and frame clinical adoption.
Recent Advances
Phillips (2020; 1060 citations) on prostate oligomets, Gückenberger (2020; 987 citations) on consensus definitions, Miften (2018; 983 citations) on IMRT QA—extend applications beyond lung.
Core Methods
4DCT planning (Keall 2006), NTCP modeling (Marks 2010), hypofractionation (Onishi 2004), motion-compensated delivery, IGRT verification (Miften 2018).
How PapersFlow Helps You Research Stereotactic Body Radiation Therapy
Discover & Search
Research Agent uses searchPapers for 'SBRT lung cancer toxicity' retrieving Timmerman (2010; 2468 citations), citationGraph maps impact to Rusthoven et al. (2009), findSimilarPapers expands to oligometastases, exaSearch scans 250M+ OpenAlex papers for unpublished trials.
Analyze & Verify
Analysis Agent applies readPaperContent to extract survival curves from Timmerman (2006), verifyResponse with CoVe cross-checks toxicity rates against Marks et al. (2010) NTCP data, runPythonAnalysis fits Kaplan-Meier curves via lifelines library and computes HR=0.67 for SBRT vs observation, GRADE scores high for phase II evidence.
Synthesize & Write
Synthesis Agent detects gaps in central tumor fractionation post-Timmerman (2006), flags contradictions between Japanese (Onishi et al., 2004) and US regimens, Writing Agent uses latexEditText for dosimetric tables, latexSyncCitations links 10 SBRT papers, latexCompile generates review manuscript, exportMermaid diagrams motion management workflows.
Use Cases
"Compare toxicity rates in central vs peripheral lung SBRT trials"
Research Agent → searchPapers + citationGraph (Timmerman 2006) → Analysis Agent → readPaperContent + runPythonAnalysis (extracts grade 3+ rates: 45% central vs 10% peripheral, t-test p<0.001) → outputs verified meta-table.
"Draft LaTeX review on SBRT for oligometastases"
Synthesis Agent → gap detection (post-Rusthoven 2009) → Writing Agent → latexGenerateFigure (isodose plots) + latexSyncCitations (Phillips 2020) + latexCompile → outputs 12-page PDF with 15 citations.
"Find code for 4DCT respiratory motion simulation"
Research Agent → searchPapers 'AAPM TG76a motion models' → Code Discovery → paperExtractUrls (Keall 2006) → paperFindGithubRepo → githubRepoInspect → outputs Python scripts for gating simulation validated against 2211-cited benchmarks.
Automated Workflows
Deep Research workflow conducts systematic SBRT review: searchPapers (50+ papers) → citationGraph → DeepScan (7-step toxicity analysis with GRADE checkpoints) → structured report comparing Timmerman regimens. Theorizer generates NTCP model hypotheses from Marks (2010) + Phillips (2020) data via runPythonAnalysis. DeepScan verifies motion mitigation efficacy chaining Keall (2006) with Onishi (2004) outcomes.
Frequently Asked Questions
What defines SBRT?
SBRT delivers 7-60 Gy in 1-5 fractions to <5 cm extracranial targets with <1 mm precision, distinct from SRS by larger fields and motion management (Timmerman, 2010).
What are core SBRT methods?
Image-guided setup, 4DCT motion assessment, VMAT/IMRT delivery, and IGRT verification per AAPM TG218 (Miften et al., 2018; 983 citations). Japanese regimen: 48 Gy/4fx; RTOG: 54 Gy/3fx (Onishi et al., 2004).
What are key SBRT papers?
Timmerman (2010; 2468 citations) established 55.8% survival; Rusthoven (2009; 1089 citations) validated metastases; Timmerman (2006; 1524 citations) defined central toxicity.
What are open SBRT problems?
Optimal central lung fractionation lacks phase III data post-2006 trial. Oligometastatic definitions vary (Gückenberger et al., 2020). NTCP models underperform for V20>30% (Marks et al., 2010).
Research Advanced Radiotherapy Techniques with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Stereotactic Body Radiation Therapy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
Part of the Advanced Radiotherapy Techniques Research Guide